



# **TAVI procedures at University Hospital of Split**

Ivica Kristić, MD PhD Andrija Matetić, MD

Interventional cardiologists






## **Severe symptomatic aortic stenosis**

Intervention is recommended in symptomatic patients with severe, high-gradient aortic stenosis [mean gradient  $\geq$ 40 mmHg, peak velocity  $\geq$ 4.0 m/s, and valve area  $\leq$ 1.0 cm<sup>2</sup> (or  $\leq$ 0.6 cm<sup>2</sup>/ m<sup>2</sup>)].<sup>235,236</sup>

В

SAVR is recommended in younger patients who are low risk for surgery (<75 years<sup>e</sup> and STS-PROM/EuroSCORE II <4%)<sup>e,f</sup>, or in patients who are operable and unsuitable for transfemoral TAVI.<sup>244</sup>

21.12.2022



TAVI is recommended in older patients ( $\geq$ 75 years), or in those who are high risk (STS-PROM/EuroSCORE II<sup>f</sup> >8%) or unsuitable for surgery.<sup>197-206,245</sup>


SAVR or TAVI are recommended for remaining patients according to individual clinical, anatomical, and procedural character-istics.<sup>202-205,207,209,210,212 f,g</sup>

в

Α

Estimated annual numbers of transcatheter aortic valve implantation candidates in different countries **under current indications (2018**)







**Dalmatia** 

## Local population:


## ~1,000,000 inhabitants of Croatia

+ inhabitants of Bosnia & Hercegovina


21.12.2022




5



•••







.

9

Table 1. Patient characteristics.


Variables	Sample (N=228)	
Age (years)	81 (77-84)	
Sex:		
Female	105 (46.0%)	
Male	123 (54.0%)	
Length of stay (days)	5 (3-7)	
Specific valve type:		
Evolut	144 (63.2%)	
Sapien	74 (32.5%)	
<b>MyVal</b>	7 (3.1%)	
Accurate NEO	3 (1.3%)	
30-day mortality	4 (1.8%)	
Permanent pacemaker rate	13 (5.9%)	
Vascular access complication		
requiring surgery	6 (2.7%)	
Stroke rate	5 (2.2%)	

Data are expressed as median (IQR) and number (percentage). Abbreviations: None.

21.12.2022

.


# Adoption of best procedural strategies



# **Procedural analgosedation**

- Following world trends
- Shift from general anesthesia to independent procedural analgosedation:
  - Education of the Team members
  - Educational visits to surgical procedures with the focus on anesthesiological work
  - Equipment preparation
  - CathLab organization


21.12.2022




Local CathLab setup

# **Procedural analgosedation**

- Final results and benefits:
  - Simplification of the procedure
  - Time gain and less ,,trauma" for the patient
  - More sense for the needs of the TAVR patient
  - Stronger involvement of the nurses and other medical staff
  - Knowledge broadening








CoreValve ® Deployment

# Vascular access

- First procedures were done with the help of cardiothoracic surgeons who enabled a surgical cut down
- Strong caution with vascular access due to possibility of deteriorating complications
- Introduction and familiarization with the vascular closure devices and full percutaneous approach
- Establishment of local protocols





# **Procedural pacing methods**


- Initial procedure were done using a mandatory temporary pacemaker insertion
- After a number of procedure, rapid over-the-wire pacing has been initiated for self-expandable valves
- Local modified protocol was developed...

21.12.2022


A. Option 1 (Split Protocol) **Positive pole** Negative pole Left ventricle inferior Vein Cava

Local protocol

## **Complex cases**



Heavy calcification



# Crack and pave

## Subclavian

access

Bicuspid valves




Bicuspidal valve

and

Icicle calcification w/ significant calcium spine Min. Ø: 17,1 mm Max. Ø: 27,7 mm Perimeter derived Ø: 27,3 mm Perimeter: 85,7 mm

# ...and dilated aorta






Steady enrollment in complex procedures


Valve-invalve PPM Trifecta 21 mm w/o BVF

21.12.2022



AV I

Several cases of LM protection (snorkel technique) at our centre...







# **Our future goals**

- Introduction of other valves
- Further training of the TAVR team
- Further standardization of the TAVR procedure
- Reduction of complications to residual levels
- Treatment of more complex patients
- Introduction of other access sites
- Introduction of other structural heart procedures










# **Case report**




## Transfemoral TAVI feasible


- Symptomatic severe aortic stenosis (progressive dyspnea, intermittent stenocardia)
- ECHO: LVEF ~65%, AV-Vmax ~5.04 m/s, MPG ~57mmHg, MR 2+.
- Aortopathy
- Bicuspid aortic valve (Sievers 0)
- Coronary angiography: non-significant changes.
- Comorbidities: hypertension; dyslipidemia; permanent atrial fibrillation (CHA<sub>2</sub>DS<sub>2</sub>VASc 4; HAS-BLED 2)







#### ANNULUS







Distance: 4,0 mm

Min. Ø: 20,2 mm Max. Ø: 25,2 mm Perimeter derived Ø: 25,5 mm Perimeter: 80,2 mm




















#### **Patient Evaluation Criteria**

Valve Size Selection	CoreValve® Evolut® R				
Size	23 mm	26 mm	29 mm	34 mm	
Annulus Diameter	18-20 mm	20-23 mm	23-26 mm	26-30 mm	
Annulus Perimeter†	56.5-62.8 mm	62.8-72.3 mm	72.3-81.7 mm	81.7-94.2 mm	
Sinus of Valsalva Diameter (Mean)	≥ 25 mm	≥ 27 mm	≥ 29 mm	≥ 31 mm	
Sinus of Valsalva Height (Mean)	≥ 15 mm	≥ 15 mm	≥ 15 mm	≥ 16 mm	








Predilatation 25x40 mm








Implantation of Evolut R 34








Evolut R 34

Team decision to perform postdilatation

(26x40 mm)








Evolut R 34

**Final result** 





## **Few hours later...**









••••








**Emergent CT aortography:** 


- Hematopericardium (up to 16 mm)
- Implanted valve is in direct contact to aortic wall near RCA, with consequent intimal injury and type A aortic dissection that spreads to the level of brachiocephalic trunk.
- Pleural effusion billateral (45 HU hemorrhagic)



**Surgical consultation:** 


"At the moment of examination, the patient is hemodynamically and respiratory stable. Imaging data has been reviewed. It is recommended to continue watchful waiting with the administration of Octaplex. Surgical control if necessary."

### After the initial blood transfusion, the patient is constantly stable.





## Controlled MSCT aortography (after ~2 weeks)













- Annular rupture is a devastating complication of TAVI, but *watchful waiting* in selected patients may be reasonable
- Patient-related factors such as **bicuspid valve**, **aortopathy** and **severe calcification**, as well as procedure-related factors such as **aggresive postdilatation**, increase the risk of annular rupture
- Increased awareness is important to further reduce the occurrence of this devastating event





# elcome to Split